Here are five key notes:
1. NuVasive made the acquisition to advance its material science portfolio and complement the company’s position as an innovator in the spine space.
2. Post-acquisition, NuVasive will be the only device company to offer porous interbody technology with both PEEK and titanium materials.
3. NuVasive’s future go-to-market plans include adding Vertera Spine’s FDA-cleared products to commercial offerings and applying the porous PEEK technology to future products.
4. The terms of the agreement were not disclosed.
5. Vertera Spine’s implants are designed to encourage bone ingrowth based on pre-clinical studies.
More articles on orthopedic devices:
Medtronic receives recognition for social responsibility
NuVasive receives FDA clearance for redesigned Magec system
Stryker completes Novadaq Technologies acquisition
